Forte Biosciences
FBRX
FBRX was delisted on the 26th of August, 2026.
39 hedge funds and large institutions have $3.01M invested in Forte Biosciences in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 16 closing their positions.
0.44% less ownership
Funds ownership: 1.07% → 0.63% (-0.44%)
25% less funds holding
Funds holding: 52 → 39 (-13)
56% less capital invested
Capital invested by funds: $6.83M → $3.01M (-$3.83M)
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
89% less call options, than puts
Call options by funds: $143K | Put options by funds: $1.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$308K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$115K |
| 3 |
Millennium Management
New York
|
+$75K |
| 4 |
E
Ergoteles
New York
|
+$64K |
| 5 |
Renaissance Technologies
New York
|
+$34.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$1.15M |
| 2 |
BlackRock
New York
|
-$752K |
| 3 |
State Street
Boston,
Massachusetts
|
-$576K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$191K |
| 5 |
Two Sigma Investments
New York
|
-$145K |
FBRX Hedge Fund Activity: Q2 2022 in Review
39 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q2 2022, worth a combined $3.01M — down 56% from $6.83M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of FBRX and 6 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $308K. The largest seller was Nuveen, exiting entirely with an estimated $1.15M sold.
- 39 institutional investors held Forte Biosciences (FBRX) as of Q2 2022, down from 52 in Q1 2022.
- Funds reported $3.01M of Forte Biosciences stock for Q2 2022, down 56% quarter-over-quarter.
- 6 funds opened new Forte Biosciences positions in Q2 2022 and 16 closed out, a net change of -10 holders.
- The largest Forte Biosciences buyer in Q2 2022 was Vanguard Group, an estimated $308K added.
- The largest Forte Biosciences seller in Q2 2022 was Nuveen, an estimated $1.15M sold.
Based on aggregated 13F filings for Q2 2022.